RxDoctor Payments Data

Julian Areiza

Family · Greenville, SCNPI 1821723107

Payments from drug & device makers

$4,676in general payments, 2019–2025

Across 288 payments — averaging $16.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • AstraZeneca$560
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$426
  • Pfizer$354
  • Novo Nordisk$220
  • Lilly USA, LLC$209
  • plus $1K from 21 others

What the payments were for

  • Food & beverage$4,676100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,676 in reported general payments places this provider in the 90th percentile of 3,248 family providers in South Carolina.

See all family providers in South Carolina

Medicare billing

Part B allowed, 2024
$15,922
Medicare patients
57
Services billed
326

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol43$58,386
JardianceEmpagliflozin41$45,024
OzempicSemaglutide38$37,588
MounjaroTirzepatide25$34,485
Trelegy ElliptaFluticasone/Umeclidin/Vilanter33$30,593
Breztri AerosphereBudesonide/Glycopyr/Formoterol30$24,043
EliquisApixaban16$23,117
VraylarCariprazine Hcl15$22,051
LinzessLinaclotide11$6,960
Lantus SolostarInsulin Glargine,hum.Rec.Anlog37$4,513
Albuterol Sulfate HfaAlbuterol Sulfate66$2,433
Gabapentin83$1,443
Atorvastatin Calcium184$1,337
Celecoxib43$920
Levothyroxine Sodium119$918

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere$560$82,42973 claims
Boehringer IngelheimJardiance$80$45,02441 claims
Novo NordiskOzempic$220$37,58838 claims
Lilly USA, LLCMounjaro$209$34,48525 claims
GSKTrelegy Ellipta$197$30,59333 claims
AbbVieVraylar, Linzess$1,491$29,01126 claims
PfizerEliquis$354$23,11716 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,248 family providers in South Carolina.

Other family in Greenville

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →